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Summary  
 
Musculoskeletal aging is a major public health concern due to demographic 
population changes. Sarcopenia, the age related loss of muscle mass and function, 
is associated with significant personal morbidity and public health care costs; it is 
associated with falls, loss of independence in older adults, and hospitalisation with 
poorer health outcomes among those affected. Just as for adult bone mass, muscle 
mass and strength increases in late adolescence and early adulthood, but then 
begins to decline significantly from the age of around 50 years. In addition to the 
personal burden of sarcopenia there are very significant public health costs 
associated with the condition; in the USA these have recently been estimated to 
be $18.5 billion for the year 2000 alone. The aetiology of development of 
sarcopenia is complex, and includes loss of muscle mass, altered muscle 
composition, infiltration with fat and fibrous tissue and alterations in innervation. 
It is hoped a better understanding of these factors will help us develop strategies 
to counteract the problem. To date, however, methodological challenges regarding 
how best to define the condition, and ongoing definitional controversy, in addition 
to uncertainty about what outcome measures might be considered have delayed 
research into possible therapeutic options. Emerging pharmacological agents have 
largely been hormonal (testosterone and SARMs) although recent work has seen 
the emergence of a promising monoclonal antibody to myostatin, and ActRIIB 
signalling blockade as new developments. 
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Introduction 
Demographic shifts in the population mean that the number of older adults in 
society has expanded hugely; the population aged over sixty years worldwide is 
predicted to rise from 841 million in 2013 to more than 2 billion by 2050. 
Musculoskeletal (MSK) disease is a significant burden on the aging population, 
contributing 7.5% of the disease burden in those over 60 years (1). The 
development of both osteoporosis and sarcopenia in later life (2,3) are a common 
problem encountered as part of musculoskeletal aging, and contribute very 
significantly to this burden on a personal and societal level. Research into 
sarcopenia has perhaps been hampered by uncertainty regarding how best to 
define the condition (3) (Table 1); indeed the very term sarcopenia, from the 
Greek meaning loss of flesh, was only first suggested in 1989 (4), and the 
incorporation of the concept of loss of muscle function as well as muscle mass with 
age has been a more recent development. However, controversy remains.  
 
Sarcopenia is associated with a number of adverse outcomes including falls, 
fractures, frailty and mortality. Physical function impairment (but not 
multimorbidity) was predictive of mortality in older community-dwellers in the 
ilSIRENTE prospective cohort study (5). The physical frailty phenotype 
operationalized by Fried (6) predicts many of the negative outcomes described 
above, and indeed it is thought that muscle loss is the mediator of this association. 
Given the interconnection between sarcopenia and frailty, it is not surprising that 
there has emerged a large literature designed to identify strategies to prevent 
development of progression of these twin pathologies; perhaps inevitably this 
literature presents the case for use of biomarkers to identify those at greatest risk, 
although to date no single biomarker has been identified (7).  
 
Lifestyle factors are known to be important in the prevention of sarcopenia; 
muscle mass and strength peak in early adulthood and subsequently decline 
significantly with age from approximately the fifth decade although individuals lose 
about 1 percent of their lean muscle mass per year after age 40. Total muscle 
mass decreases by nearly 50 percent for people between the ages of 20 and 90 
(8). On average, people lose about 30 percent of their strength between ages 50 
and 70, and another 30 percent of residual mass per decade after that. Analagous 
to bone loss, adoption of a more sedentary lifestyle in adolescence and young 
adulthood in recent years, and an extended life expectancy, might lead the reader 
to conclude that the prevalence of sarcopenia and associated health consequences 
will increase very significantly in the coming years. 
 
How common is sarcopenia and what are the estimated costs associated 
with the condition? 
Varying definitional approaches to sarcopenia will of course impact upon the 
prevalence estimates of the condition; figures have been quoted as ranging from 
9% to 18% in individuals over 65 years of age, rising further to 30% in men over 
80 and even higher in hospitalised patients (8,9). This is because in individuals 
over the age of 50 years, muscle mass is lost at a rate of 1-2% per year and 
strength at a (slightly greater) rate of 1.5-3% per year (10).  As alluded to 
previously, definitions of sarcopenia have only recently been proposed and are still 
not fully accepted. If we apply these approaches to community dwelling cohorts 
such as the UK based Hertfordshire Cohort Study, a   prevalence of 4.6% and 
7.9% can be demonstrated among men and women respectively at a mean age 
of 67 years (11).  
 
Unlike for osteoporosis, where the clear consequence of the condition is fragility 
fracture, the outcome associated with sarcopenia that is important and 
quantifiable in public health terms is much harder to define. Loss of independence 
is clearly important; it has been suggested that while loss of 30% of reserve 
capacity limits normal function, a loss of 70% results in system failure (12). This 
has been demonstrated in studies that illustrate that sarcopenia predicts loss of 
independence for activities of daily living in older men and women (13,14); for 
example, ability to walk (which may be limited by sarcopenia) is associated with 
increased healthcare costs (15), and sarcopenia is associated with a higher risk of 
falling, which leads to loss of independence and hospitalisation costs (16). 
Sarcopenia is also a predictor of poor outcomes in patients who are undergoing 
surgery or have other serious co-morbidities (17-19). 
 One of the very few studies that tried to estimate the economic costs associated 
with sarcopenia in the US reported an estimate of $18.5 billion ($10.8 billion in 
men and $7.7 billion in women) for direct costs in 2000, accounting for about 
1.5% of total health expenditure in the US (20). These costs are due to 
hospitalisation, nursing home admissions and home healthcare expenditure, and 
there is an important research agenda to quantify more recent estimates, in US 
and elsewhere in the world, perhaps attempting to put an estimate on the indirect 
costs outlined above. Given that sarcopenia may also be associated with other 
healthcare costs such as lack of productivity, reduced quality of life and 
psychological problems, research in this area is also timely, especially given the 
recent development of a quality of life tool specifically designed for sarcopenia 
(21).  
 
Definitional approached to sarcopenia 
There remains considerable ongoing international debate regarding the best 
approach to take in the definition of sarcopenia, due in part to different 
technologies that might be available to inform any definition (DXA or 
bioimpedance for example). The International Osteoporosis Foundation and 
European Society for the Clinical and Economic aspects of Osteoarthritis and 
Osteoporosis have recently contributed to this debate through publication of a 
Consensus statement, and their summary is displayed in Table 1 (2,3). The 
Foundation for the National Institutes of Health (FNIH) Sarcopenia Project has 
used data from nine sources of community dwelling older persons from the US, 
Iceland and Europe to also inform this debate. Among a pooled sample of 26,625 
participants (57% women, mean age in men 75.2 (SD 6.1) years and in women 
78.6 (SD 5.9) years), analyses recommended cut points for grip strength of <26kg 
in men and <16kg in women, and for low lean mass, appendicular lean mass 
adjusted for body mass index of <0.789 in men and <0.512 in women (22). This 
report also highlights numerous research priorities, specifically the evaluation of 
the clinical impact of a less stringent definition, epidemiological data reporting 
rates of change in lean mass over time, and a strong research agenda around 
interventions (lifestyle and pharmacological) that may retard muscle loss. 
Interestingly, similar cut points for grip strength (<27kg in men, < 16kg in 
women) have been reported from a recent work taking a life course approach to 
describing grip strength using normative data from 12 British studies (49,964 
participants), suggesting that consensus may be starting to develop with regard 
to definitional approaches (23). 
 
One of the most recent contributions has been the Asian working group for 
sarcopenia, that recommends cutoff values for muscle mass measurements (7.0 
kg/m2 for men and 5.4 kg/m2 for women by using dual X-ray absorptiometry, and 
7.0 kg/m2 for men and 5.7 kg/m2 for women by using bioimpedance analysis), 
handgrip strength (<26 kg for men and <18 kg for women), and usual gait speed 
(<0.8 m/s) (24). 
 
Biology of aging 
Muscle cells are likely to be influenced by fundamental processes of aging that 
affect all living cells. These include replicative senescence and impaired stem cell 
regeneration; accumulation of cell damage; autophagy (reduced clearance of cell 
damage) and reduced mitochondrial energy generation. A full discussion of the 
biology of aging as applied to muscle is outside the scope of this review, and has 
been recently undertaken by others (25-28). However, understanding of the 
aetiology of age related muscle loss is of course key in the development of 
therapeutic strategies to retard or prevent muscle loss, and research in this field 
is key(29). Sarcopenia involves negative protein turnover, characterised by 
reduction of myofibrillar and mitochondrial protein synthesis (25) and increased 
proteolysis by the UPS and calcium-dependent activation of proteases. Because 
mitochondria are very important in energy provision, redox homeostasis and 
regulation of cell death, many recent articles have focused on age-related 
alterations of mitochondrial function in the aetiology of sarcopenia. For example, 
one recent review (26) postulates that defective redox signalling may be important 
in reducing the integrity of the aging neuromuscular system, and a better 
understanding of the causes of defective homeostasis provides an opportunity to 
identify targeted interventions. A second review, published in 2016 (27) highlights 
the progressive reduction in the regenerative capacity of the skeletal muscle stem 
cells (satellite cells) which are critical for repair to muscle trauma or damage. 
Decreased capacity for muscle regeneration and increased apoptosis may be 
important, an assertion supported by the observation that apoptotic signalling 
correlates with slow walking speed and reduced muscle volume (28). Skeletal 
atrophy with aging is accompanied by loss of muscle strength (30) and 
neuromuscular impairment (loss of motor units and loss of motor neurons). Finally 
the therapeutic opportunities of a better understanding of the interplay between 
satellite cell extrinsic and intrinsic factors in sarcopenia are highlighted, and also 
discussed in a 2015 review by Blau et al (31).  
 
Systemic inflammation may be important in the pathogenesis of muscle loss in 
later life; increased production of proinflammatory cytokines may affect all the 
mechanisms outlined above. ‘Inflammaging’ was first proposed as a phenomenon 
in 2000, as a possible underlying cause of muscle loss (32). Inflammaging may 
result from lifetime exposure to both clinical and sub-clinical infections as well as 
exposure to non-infective antigens leading to high antigenic load (33). An 
inflammatory response is mounted, leading to tissue damage and the production 
of reactive oxygen species which result in the release of additional cytokines (34). 
This vicious cycle favours a chronic pro-inflammatory state. (35,36), and might 
also be amenable to therapeutic manipulation.  
 
Lifestyle modification to improve muscle mass and function 
Of course, just as for bone loss, a factor that is important in affecting muscle may 
influence either development of peak mass, or rates of loss, or indeed a 
combination of both factors, and the peak attained in youth may be an important 
determinant of function in later life, and will be affected by environmental and 
genetic factors, with environmental factors potentially amenable to modification. 
Grip strength over the life course is illustrated in Figure 1. Genetic factors are 
major contributors to muscle strength, and sarcopenia is expected to also be 
affected by genetic factors (10). To date, the research performed to date in this 
area has pinpointed the myostatin pathway and the vitamin D receptor gene (10).  
 
Before considering pharmaceutical interventions it is helpful to consider the 
lifestyle factors that influence muscle mass in later life, and which might be 
reviewed with good effect (Table 2). As we age, body fat increases and muscle 
mass decreases, often with relative overall stability in body weight, leading to the 
term sarcopenic obesity, which represents the coexistence of sarcopenia and 
obesity, and describes a disproportion between the amount of lean mass relative 
to fat mass. The varying definitions of sarcopenia, and obesity (although most 
studies use BMI, some studies have relied on percent body fat or visceral fat) the 
prevalence of sarcopenic obesity has been quoted as ranging from 0% to 41% in 
older populations (37). The loss of lean mass and increase in fat mass with 
advancing age may share common etiologic pathways and increases in fat mass 
and accompanying increases in adipokines and inflammation may further 
adversely affect muscle quality. The importance of research in this area was 
highlighted in a recent review of the condition (37). 
 
 
Although obese or overweight adults often have a higher muscle mass compared 
to their non-obese peers, their lean mass is low compared to their total weight 
(38). Significant weight loss is associated with rapid loss of grip strength, possibly 
reflecting coexisting comorbidity that acts as a confounder (39).  Physical activity 
is known to be very important in affecting muscle mass and strength. Inactivity 
has been shown to lead to loss of muscle mass and strength at any age. Bed rest 
studies have shown that a decrease in muscle strength occurs before a decrease 
in muscle mass (40). By contrast lifelong physical exercise has been shown to 
preserve muscle structure and function (41). Specifically, increases in mid-life 
leisure time physical activity has been shown to reduce the risk of mobility 
impairment in older adults, though interestingly occupational physical activity in 
mid-life may actually have a detrimental effect on mobility at older age (42). A 
recent systematic review also highlighted the studies that have suggested benefits 
of exercise on muscle health in later life (43); a recent review by Law et al (44) 
provides an overview of the evidence for the role of resistance exercise in the 
prevention and treatment of sarcopenia, and highlights certain critical factors- 
namely exercise intensity, volume and progression- that are key to optimizing the 
resistance exercise prescription.  
 Cigarette smoking may have direct effects on muscle as well as be associated with 
other detrimental lifestyle factors. The relationship was recently considered in the 
Minos study (45) where current smokers were shown to have lower appendicular 
muscle mass than non-smokers, and a dose-effect relationship was apparent. By 
contrast some other studies have reported no association (46). Alcohol 
consumption may also impact muscle health. While moderate alcohol intake was 
not associated with muscle mass in the Minos study (45), it might be anticipated 
that heavy alcohol consumption is likely to lead to low muscle mass through 
associated effects on poor nutrition, low levels of physical activity and hormonal 
abnormalities. 
 
Finally, dietary factors may also be helpful for maintenance of muscle mass and 
strength. We know that the rate of muscle protein synthesis may be reduced by 
30% in older people, as a result of poor nutrition, disease or reduced physical 
activity rather than aging itself (47) as well as decreased muscle protein synthesis 
per se, particularly in specific muscle fractions such as mitochondrial proteins (48). 
In a recent review of nutritional factors and muscle health by the International 
Osteoporosis Foundation (49), studies that showed that protein intake is positively 
associated with preservation of lean bone mass in men and women aged 70-79 
years were reported. In most supplementation studies protein supplementation 
has been combined with resistance training, although the results of these trials 
have been mixed (50). An ESCEO consensus statement has recently considered 
the available evidence and recommended an optimal dietary protein intake of 1.0 
to 1.2g/ kg body weight/day with at least 20-25g of high-quality protein at each 
main meal in post-menopausal women for prevention of age-related deterioration 
of musculoskeletal health (48).  
 
Vitamin D status is topical in all areas of musculoskeletal aging, and low vitamin 
D levels have been associated with poorer balance and an increased risk of falls 
(51). A raised PTH level often accompanies low vitamin D levels, and has also 
been associated with sarcopenia and risk of falling independent of 25(OH)D status 
(52), such that recent guidance recommends an adequate vitamin D intake of 
800IU/daily to maintain serum 25(OH)D levels >50 nmol/l in post-menopausal 
women (52).  
 
A systematic review published in 2014 reported moderate quality evidence that 
exercise interventions improve muscle strength and physical performance while 
the benefits of nutritional interventions were more equivocal (53). 
 
Possible therapeutic targets 
When considering the selection of patients who might enter studies of novel 
therapies to prevent or retard development of sarcopenia, it is helpful to be aware 
of the regulatory processes surrounding drug development. The IOF recently 
published recommendations specifically addressing this issue (54), and highlight 
the notion that prevention of sarcopenia in high-risk pre-sarcopenic individuals 
could be possible, as might treatment of individuals in whom sarcopenia has 
already developed.  The anabolic and catabolic signalling pathways that might be 
targeted in any therapeutic manipulation are shown in Figure 2. 
 
 Potential regulators that might be targeted to impact muscle loss include 
androgens (which act through the androgen receptor/Wnt/beta-catenin signalling 
pathway), insulin and insulin growth factor 1 (which regulate protein synthesis 
and degradation through the PI3K/AKT pathway), myostatin (which inhibits 
muscle growth), other members of the transforming growth factor beta 
superfamily, and inflammatory modulators including pro-inflammatory cytokines 
such as tumour necrosis factor-alpha and interleukin-1.  
 
Hormonal manipulation of some kind had formed the basis of many of the studies 
performed to date. Testosterone supplementation is known to increase skeletal 
muscle volume by promoting hypertrophy of myofibers, but is associated with 
significant side effects, and translation to benefits on muscle function has been 
less clearly demonstrated. Relevant to this review, Atkinson et al trialled 
transdermal testosterone gel (50mg) or placebo gel daily for 6 months in a group 
of thirty intermediate-frail and frail elderly men aged 65-89 years who were known 
to have low to borderline low testosterone, demonstrating a rise in testosterone 
from 11.6 (SD 3.5) to 18.0 (SD 8.1) nmol/l in the intervention group, coupled with 
a preservation of muscle thickness in the intervention group, compared with a 
decrease in the placebo group (55). Phase two trials have also been performed of 
an androgen receptor modulator (enobosarm), demonstrating a dose-dependent 
increase in total lean body mass, in addition to improvements in physical function 
(56). Administration of this orally administered bioavailable nonsteroidal SARM did 
not appear to be associated with an increased risk of adverse effects and the study 
group consisted of both male and female participants in their seventh decade. 
Reports of a trial using another selective androgen receptor modulator (MK-0773) 
were published in 2013 (57); in this study 170 women with sarcopenia were 
randomised in a double blind placebo controlled trial that demonstrated a 
statistically significant increase in lean body mass in the treatment group at 6 
months, without evidence of androgenisation, and although physical performance 
also improved over follow up this was not statistically significant from the placebo 
treated group. The treatment group was noted to feature several patients with 
elevated transaminases but this resolved on study discontinuation.  
 
Recent work has suggested that a humanised monoclonal myostatin antibody that 
bonds and neutralises myostatin may increase lean mass and may also improve 
functional measures of muscle power (58). A proof of concept double blind placebo 
controlled phase two trial was conducted in 201 patients aged 75 years or older 
who had fallen in the last year reported a difference of 0.43kg (95% CI 0.192 to 
0.660); significant differences in stair climbing time, chair rise with arms and fast 
gait speed were also observed between the two groups over 24 weeks (58). This 
follows previous approval for this therapy for the treatment of inclusion body 
myositis in whom a single dose of therapy resulted in an increase in 6-metre 
walking distance of 52 metres over placebo (59). 
 
In further work involving myostatin, it has been suggested that because postnatal 
blockade of the activin type IIB receptor (ActRIIB) leads to rapid and massive 
muscle hypertrophy, it may be a promising therapeutic target. The receptor is a 
transmembrane kinase receptor highly expressed in mammalian skeletal muscle 
that mediates signalling for myostatin. Therapeutic approaches have involved the 
systemic delivery of neutralising antibodies against the receptor or mysostatin, 
and injection of a soluble recombinant form of the receptor that acts as a decoy 
disputing the interaction of endogenous receptor with its ligands (60) Having 
previously been trialled in patients with muscular dystrophy, a recent study of the 
effect of receptor blockade in wild type mice demonstrated that 8 week ActRIIB 
blocade with soluble receptor increased absolute force-generating capacity and 
reduced mitochondrial function in glycolytic gastrocnemius muscle but that this 
reduction did not compromise energy status during sustained activity (60).  
 
That preventative and therapeutic strategies are required in the management of 
sarcopenia was the thesis of an article by Marzetti et al (61); they specifically 
consider mitochondrial dysfunction, highlighting the potential challenges and risks 
of such a study, as well as suggesting possible study populations. Unfortunately, 
to date no such agent is available for trial.  
 
Conclusion 
Our aging population means that conditions that emerge later in life and are 
associated with very significant personal and public health costs are of great 
significance. Sarcopenia and the linked condition frailty is perhaps one of the most 
significant of these. There has recently emerged a strong research agenda 
considering the aetiological factors that might prevent or retard the development 
or progression of sarcopenia. In the context of muscle aging, an understanding of 
the biology of aging as applied to muscle may help us to identify those at risk of 
sarcopenia, and to identify potential therapeutic targets, and a partnership 
between basic biologists, the pharmaceutical industry and clinicians seems critical. 
Given the very significant personal, societal and economic burdens associated with 
sarcopenia, it is essential that we identify ways to identify those at greatest risk, 
and use lifestyle strategies to retard or prevent muscle loss at a whole population 
approach. However, many individuals are likely to benefit from a tailored 
pharmacological approach in addition and while methodological challenges 
regarding how best to define the condition, and what outcome measure might be 
considered have delayed research into possible therapeutic options, promising 
pharmacological agents have emerged. To date these have largely been hormonal 
(testosterone and SARMs) although recent work has seen the emergence of a 
promising monoclonal antibody to myostatin.  
 
A particular challenge for clinicians who treat patients with the condition is that 
while tools have been developed that have been demonstrated to be accurate and 
reliable in research settings, many are not easily applied to clinical practice, and 
more simple tools have recently been proposed, in an attempt to facilitate 
incorporation of the research agenda into clinical practice [62-64].  A particular 
criticism of a mass based definitional approach to the condition is the relationship 
between loss in muscle strength and its relationship to muscle loss. While it has 
been demonstrated that the two are correlated, and indeed that sarcopenia 
predicts adverse functional outcome, loss of muscle strength often exceeds muscle 
loss. This is of very considerable relevance when considering definitional 
approaches – and clinical outcomes for pharmacological trials – analogous to bone 
mineral density and fracture risk, if it is functional performance that we seek to 
preserve, study designers should be cogniscent of the clinical outcome of choice. 
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 Table 1 
Diagnostic criteria for sarcopenia: suggested approaches (modified from [3]) 
Study group Definition Criteria 
ESPEN Special Interest Groups  “Sarcopenia is a condition 
characterized by loss of muscle 
mass and muscle strength. 
Although sarcopenia is primarily a 
disease of the elderly, its 
development may be associated 
with other conditions that are not 
exclusively seen in older persons, 
like disuse, malnutrition and 
cachexia. Like osteopenia, it can 
be also be seen in those with 
inflammatory diseases.” 
1. Low muscle mass, e.g. 
percentage of muscle mass >2 
SDs below mean in individuals 
aged 18–39 y in the NHANES III 
cohort 
2. Walking speed <0.8 m/s in the 
4-min test or reduced 
performance in any functional 
test used for the 
comprehensive geriatric 
assessment 
European Working Group on 
Sarcopenia in Older People  
“Sarcopenia is a syndrome 
characterized by progressive and 
generalized loss of skeletal muscle 
mass and strength with a risk of 
adverse outcomes such as 
physical disability, poor quality of 
life and death.” 
The condition is called primary 
sarcopenia when the cause is 
aging per se, and secondary 
sarcopenia when disease, 
inactivity, or malnutrition 
contribute 
1. Low muscles mass 
2. Low muscle strength (e.g. grip 
strength) 
3. Low physical performance (e.g. 
gait speed) 
Reference population of healthy 
young subjects using cutoff points 
<2 SDs below mean. Criterion 1 
and Criterion 2 or 3. 
International Working Group on 
Sarcopenia  
“Sarcopenia is defined as the age-
associated loss of skeletal muscle 
mass and function. The causes of 
sarcopenia are multifactorial and 
can include disuse, altered 
endocrine function, chronic 
disease, inflammation, insulin 
resistance, and nutritional 
deficiencies. While cachexia may 
be a component of sarcopenia, 
the two conditions are not the 
same.” 
1. Gait speed <1 m/s 
2. Objectively measured low 
muscle mass, e.g. appendicular 
mass relative to height 
squared, i.e. ≤7.23 kg/m2 in 
men and ≤5.67 kg/m2 in 
women 
Society of Sarcopenia, Cachexia 
and Wasting Disorders  
“Sarcopenia with limited mobility 
is a specific condition with clear 
loss of muscle mass and a clear 
target for intervention. As such it 
1. Walking speed ≤1 m/s or 
walking distance <400 m 
during a 6-min walk 
2. A lean appendicular mass 
corrected for height squared of 
differs from the more general 
concept of frailty.”  
“The limitation in mobility should 
not be clearly attributable to the 
direct effect of specific disease, 
such as peripheral vascular 
disease with intermittent 
claudication, or central and 
peripheral nervous system 
disorders (such as stroke, 
Parkinson’s disease, spinal cord 
disease, or motor neuron disease), 
dementia, or cachexia.” 
>2 SDs below the mean of 
healthy persons aged between 
20 and 30 y of the same ethnic 
group 
Foundation for the National 
Institutes of Health Sarcopenia 
Project (FNIH) 
“Low muscle mass and weakness 
are common and potentially 
disabling in older adults, but in 
order to become recognised as a 
clinical condition, criteria for 
diagnosis should be based on 
clinically relevant thresholds and 
independently validated. Based on 
a pooled sample of 26,625 
participants, final recommended 
cutpoints for weakness and low 
lean mass are presented. ” 
ALM adjusted for BMI – 
men<0.789; women<0.512 
Grip strength – men<26kg; 
women<16kg 
Gait speed <=0.8 m/s 
  
 
Asian working group for 
sarcopenia 
‘sarcopenia should be described 
as low muscle mass plus low 
muscle strength and/or low 
physical performance, and we also 
recommend outcome indicators 
for further researches, as well as 
the conditions that sarcopenia 
should be assessed’. 
Cutoff values for muscle mass 
measurements:  7.0 kg/m2 for 
men and 5.4 kg/m2 for women by 
using dual X-ray absorptiometry, 
and 7.0 kg/m2 for men and 5.7 
kg/m2 for women by using 
bioimpedance analysis, 
handgrip strength handgrip 
strength (<26 kg for men and <18 
kg for women) 
 usual gait speed (<0.8 m/s) 
Table 2 
Risk factors for muscle aging (adapted from [46]) 
 
Constitutional Lifestyle 
 
Low body weight 
Age Cigarette smoking 
 
Excessive alcohol 
consumption 
Sex hormone deficiency Prolonged immobilisation 
Early environment 
 
 Low protein intake 
Co-morbidity Vitamin D deficiency 
Genetic Factors 
 
Use of ACE inhibitors 
Use of steroids 
Low growth hormone level  
  
  
 
  
Figure 1. Reference data for grip strength across the lifecourse in the 
HALCyon Consortium: 14 cohorts. Reproduced with permission from 
Dodds R et al  PLOS One 2014; 9: e113637 
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Figure 2. Anabolic and catabolic signalling pathways in muscle 
 
 
Androgens, GH mimetics & follistatin – anabolic pathways        Myostatin & ubiquitin ligases - catabolic pathways  
 
 
 
